In 2003, genetic scientists exceeded their own expectations and completed mapping the entire human genome 3 years in advance of the projected deadline. It has been a fast climb since Watson and Crick ...
TOKYO & BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced initial results ...
The FDA has approved Seattle Genetics' breast cancer drug Tukysa (tucatinib) four months early, including in certain patients whose disease has spread to the brain. Tukysa has been approved in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback